Adeshwar Meditex Ltd.

Adeshwar Meditex Ltd.

BBSE:ADESHWAR
17.00
INR
-1.80
(-9.57%)
245.05MMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
40.55
36.62
45.55
45.71
44.78
57.04
55.26
57.98
38.85
- -
Basic EPS, GAAP
1.77
1.56
1.16
1.16
0.55
1.44
1.39
1.43
0.88
- -
Free Cash Flow per Basic Share
-0.82
-4.36
1.96
1.96
-2.5
3.16
2.36
2.53
3.39
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
9.39
10.95
13.04
14.26
21.45
22.81
24.19
25.61
26.53
26.53
Tangible Book Value per Share
9.37
10.93
13.02
14.25
21.45
22.8
24.19
25.61
26.53
26.53
Basic Weighted Avg Shares
14
14
14
14
14
14
14
14
14
14
Sales/Revenue/Turnover
585
528
657
660
646
823
797
837
561
- -
Operating Margin (%)
8.81
6.68
6.86
6.67
4.66
5.69
5.74
4.7
4.18
- -
Depreciation Expense
4
4
4
4
4
5
6
5
4
- -
Net Income, GAAP
26
23
17
17
8
21
20
21
13
- -
Effective Tax Rate (%)
28.55
27.89
28.33
28.33
33.43
28.59
27.91
26.05
30.95
- -
Profit Margin (%)
4.38
4.26
2.55
2.54
1.23
2.52
2.52
2.47
2.26
- -
Working Capital
109
170
208
212
280
282
294
332
346
346
LT Debt
5
50
61
54
41
23
11
19
17
17
Total Equity
135
158
188
206
310
329
349
370
383
383
Return on Invested Capital (%)
- -
12.01
8.21
7.29
4.29
6.73
6.71
5.91
3.45
- -
Return on Capital (%)
- -
12.68
8.43
7.81
4.48
6.99
6.62
6.05
3.54
- -
Return on Common Equity (%)
- -
15.34
9.69
8.52
3.08
6.5
5.92
5.75
3.36
- -

Capital Structure

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
105
29
43
LT Borrowings
19
32
17
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
242
249
245

Working Capital

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
661
567
445
Cash, Cash Equivalents & STI
20
- -
- -
Accounts Receivable, Net
350
325
208
Inventories
258
218
205
Total Current Liabilities
329
214
98
Payables & Accruals
- -
- -
- -
ST Debt
105
29
43
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.44%
3.57%
Free Cash Flow
- -
-87.69%
34.05%
Net Income, GAAP
- -
13.95%
-38.77%
Sales/Revenue/Turnover
- -
-1.17%
-32.99%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
797
2025
- -
- -
837
2026
- -
- -
561

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.39
2025
- -
- -
1.43
2026
- -
- -
0.88

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Ashalata Baburao Raut
Full Time Employees
24
Sector
Health technology
Industry
Medical specialties
Address
Lok Centre Mumbai MA India 400059
IPO Date
Jun 28, 2021
Business
Adeshwar Meditex Limited manufactures and exports sterile surgical wound dressings, medical disposables, and related healthcare products from its headquarters in Mumbai, India; the company, with roots established in 1951 and formally incorporated in 2007, holds certifications including cGMP, CE, and ISO 13485:2012, and operates primarily from facilities in Maharashtra with exports to international markets. Its core offerings encompass sterile surgical wound dressings such as gauze, cotton wool rolls, combined dressings, and tulle dressings including brands like Petronet, Bactigauze, Polybabe, Povidine, Nitrofurazone Gauze, Framytulle, and Fusitulle; medical bandages and adhesive plasters for wound support and protection; antiseptics and disinfectants for infection prevention; first aid kits for home, office, and travel use containing bandages, plasters, and essentials; surgical plastics including trays and instruments; other disposables such as surgical gloves, masks, and gowns; advanced hemostatic products like chitosan, oxidized cellulose, and gelatin sponges; Home Based New Born Care (HBNC) kits; and face masks, with customizable solutions and turnkey projects available for healthcare facilities. The company recently redesignated Krishnojirao Nagaraja Rao as chairperson in August 2024 and appointed Satish Chudekar as a non-executive, non-independent director in September 2025, alongside reporting audited financial results for the fiscal year ended March 31, 2025, with profits of INR 2.07 crore and no fund-raising deviations.